Radiation-induced lung injury: current evidence.
Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. · 2021
Read Radiation-induced lung injury: current evidence. by Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7788688.txt.
Introduction
Arroyo-Hernández and co-authors review radiation-induced lung injury. Radiation and drug therapy work well for chest cancers. Lung damage is the dangerous side effect. Inflammation of the lung, called pneumonitis, can be life-threatening.
The injury unfolds in two phases. Early radiation pneumonitis is acute lung inflammation. Late radiation fibrosis is lasting tissue damage. Damage comes from direct cell killing, oxidative stress, and immune attack. Diagnosis rests on ruling out other causes with scans and clinical checks. Lung function tests help predict risk during treatment. Steroid drugs are the standard treatment for pneumonitis. The authors give practical advice on prevention, diagnosis, and care.
Catalog record
| CREATOR | Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Radiation-induced lung injury: current evidence By Marisol Arroyo-Hernández, Federico Maldonado, Francisco Lozano-Ruiz, Wendy Muñoz-Montaño, Mónica Nuñez-Baez, Oscar Arrieta Published in: BMC Pulmonary Medicine DOI: 10.1186/s12890-020-01376-4 ABSTRACT Abstract Chemo-radiotherapy and systemic therapies have proven satisfactory outcomes as standard treatments for various thoracic malignancies; however, adverse pulmonary effects, like pneumonitis, can be life-threatening. Pneumonitis is caused by direct cytotoxic effect, oxidative stress, and immune-mediated injury. Radiotherapy Induced Lung Injury (RILI) encompasses two phases: an early phase known as Radiation Pneumonitis (RP), characterized by acute lung tissue inflammation as a result of exposure to radiation; and a late phase called Radiation Fibrosis (RF), a clinical syndrome that results from chronic pulmonary tissue damage. Currently, diagnoses are made by exclusion using clinical assessment and radiological findings. Pulmonary function tests have constituted a significant step in evaluating lung function status during radiotherapy and useful predictive tools to avoid complications or limit toxicity. Systemic corticosteroids are widely used to treat pneumonitis complications, but its use must be standardized, and consider in the prophylaxis setting given the fatal outcome of this adverse event. This review aims to discuss the clinicopathological features of pneumonitis and provide practical clinical recommendations for prevention, diagnosis, and management. Keywords: Pneumonitis, Radiation pneumonitis, Radiation-induced lung injury, Lung cancer, Radiotherapy, Antineoplastic agents, Adverse effects BACKGROUND For many years, radiotherapy (RT) has played an essential role in cancer treatments applied with curative intent or as an adjuvant treatment with chemotherapy or surgery [1]. It has also been used as a palliative remedy to alleviate symptoms in malignant and non-malignant disorders [2]. However, radiation-induced lung injury (RILI) is a severe complication of thoracic RT and embraces radiation pneumonitis (RP) and radiation fibrosis (RF) [3]. With the advent of new forms of radiotherapy techniques, such as Stereotactic Body Radiation Therapy (SBRT) and Intensity-modulated radiotherapy (IMRT), delivery of beam arrays to the tumor and surrounding tissues is more precise, reducing the incidence of lung toxicity. Risk factors related to the patient, treatment, and tumor can all influence the severity and extent of lung injuries. The challenge for diagnoses relies on the different clinical-radiological presentations and exclusion of alternative diagnoses, which explain the broad range of incidence rates (5%-58%) [4–7]. MAIN TEXT Predisposing factors Treatment-related factors - Radiation therapy: RILI encompasses any lung damage due to lung exposure to ionizing radiation. This damage typically classified in early and late radiation toxicity could oscillate between asymptomatic and severe manifestations. Three common grading systems have used to stratify the severity of symptoms (see Table 1) [8]. In almost 40% of cases, conventional RT irradiates a considerable extension of healthy tissue surrounding the tumor. Therefore, new technologies of treatment delivery explored intensity-modulated RT (IMRT), volumetric arc radiotherapy (VMAT), and stereotactic body radiation therapy (SBRT) to highly individualized radiation treatment for primary tumors to minimize lung injury. In general, these techniques are well-tolerated, although major lung toxicity reported in up to 20% of cases [9, 10]. - Lung dose: The total lung radiation dose is the main factor that predisposes to RP. The radiation doses delivered to the percentage of healthy lung tissue, receiving at least 20 Gy (V20), link to the development of lung toxicity [11, 12]. Additionally, low-dose parameters in the ipsilateral lung such as V5, V10, and V13 are also related to the development of RP [13, 14]. Mean Lung Dose (MLD), or the average dose in proportion to total lung volume, has been reported as the best predictor of RP grade > 3 (OR, 1.002; 95% IC, 1.000–1.003; p = 0.03) [15]. - Fractionation: For SBRT, the total dose of radiation treatment (40–70 Gy) is divided into large doses by fractions, thus shortening exposure time (1–2 weeks). When larger doses per fraction used (e.g., 50 Gy in 5 fractions), V20 > 10%, and a mean lung dose > 6 Gy are associated with a higher risk of RP grade ≥ 2 [16]. A recent multicenter trial compared the impact of the fractionation scheme—daily vs. every other day—on toxicities. There, the patients treated daily experienced significantly higher grade > 2 toxicities than the every-other-day patients (43 vs. 7%, p < 0.001) [17]. - Chemotherapy: Chemotherapeutic agents like doxorubicin, taxanes, bleomycin, cyclophosphamide, vincristine, mitomycin, gemcitabine, and bevacizumab recognized as radiotherapy sensitizers due to their synergistic effect [18–20]. Taxane-induced pneumonitis seems to be higher when these agents combined with other cytotoxic drugs, especially gemcitabine. - Concurrent treatment with chemo-radiotherapy (CCRT): Patients who receive combinations with cytotoxic agents have a higher frequency of lung toxicity compared with those who receive monotherapy (32 vs. 6%) [5, 21]. Remarkable, in an international cohort, radiation pneumonitis was increased in patients > 65 years treated with a platinum-taxanes combination [21]. However, a 2012 meta-analysis with over 1,600 patients demonstrated an increased OR of 1.6 (1.11–2.32) for RP in patients receiving concurrent treatment compared to sequential chemotherapy [22]. Furthermore, induction chemotherapy before concomitant treatment could increase the risk of RP, probably due to the prior radiosensitizing contribution of chemotherapy [23]. - Y90 microsphere radioembolization: Radioembolization delivers directed intraarterial doses of yttrium-90 (Y90) for treating hepatocellular carcinoma and liver metastases. RP is one of the most critical risks of radioembolization. Significant shunting to the lungs may result in lung toxicity, which has related to lung shunt fraction of more than 13% [24, 25]. During the planning of Y90 radioembolization, the assessment of splanchnic and pulmonary shunting may predict lung deposition of microspheres, and the risk for RP [26]. - Immunotherapy: Pneumonitis due to immunotherapy is a rare but potentially life-threatening immune-related Adverse Event (irAE) derived from a direct cytotoxic effect, oxidative stress, and immune-mediated injury. The time elapsed between immunotherapy and the presence of pneumonitis varies from 1 to 24 months [27, 28]. Combined treatment with anti-PD1/PD-L1 increases pneumonitis risk by 1.5–2 times, moreover, anti-PD-1/PD-L1 combined with anti-CTLA-4 risk is 10% compared to the use of monotherapy (3%) [29, 30]. Furthermore, combination strategies of nivolumab and tyrosine-kinase inhibitors concomitantly or sequentially increase the risk of pneumonitis considerably [31]. Pneumonitis recurrence after rechallenge occurs in 60% of patients, and some cases even more extensively and severely [32–34]. Safety in re-treatment with immune checkpoint inhibitors does not depend entirely on the severity of the initial adverse event. [Table: Grading system for radiation induced lung toxicity] Tumor-related factors - Tumor location: Disease location in the mid-lower lung is more strongly associated with the development of RP [22, 35, 36]. Two possible explanations are 1) tumor motion may require a large lung radiated volume [37] and 2) patients can have inhomogeneous perfusion before RT due to previous lung diseases, tissue infiltrates, and cancer involvement. Thus, radiation may cause damage, which decreases perfusion and increases tissue density. - Tumor histology and staging: No association has yet been reported between tumor histology and RP development, while the effect of tumor stage in predicting RP risk is controversial. - Tumor volume: Patients with a higher tumor volume usually have a more significant lung and surrounding radiated volume. The most crucial factor that influences the development of RP is thus related to the percentage of lung radiated volume [13, 38]. Patient-related factors - Smoking: Smoking is deleterious for survival, noteworthy the effect on the increased risk of developing RILI is not clear. There is evidence that smoking